Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration Repare Therapeutics (Nasdaq: RPTX) announced a definitive asset purchase agreement under which Gilead Sciences will acquire Repare’s Polθ ATPase inhibitor, RP-3467, for up to $30 million in total consideration.Deal terms include a $25 million upfront payment subject to customary holdbacks and adjustments and an additional $5 million payable upon completion of specified technology transfer activities. Repare said the upfront cash increases its estimated Closing Net Cash Amount under a separate arrangement in which Xeno will acquire Repare, and Repare now estimates a cash payment of approximately US$2.20 per common share at the Arrangement Closing.

#RPTX Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

www.stocktitan.net/news/RPTX/repare-therape...

Thanksgiving Insights: M&A Legal Investigations by Monteverde Firm Unveiled As Thanksgiving arrives, the Monteverde Class Action Firm investigates major mergers involving RPTX, AXTA, WTG, and SEMR, examining their fairness for shareholders.

Thanksgiving Insights: M&A Legal Investigations by Monteverde Firm Unveiled #United_States #New_York #RPTX #AXTA #Monteverde_Class_Action

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. Repare Therapeutics (Nasdaq: RPTX) announced that certain affiliates of BVF Partners, Blue Owl Healthcare Opportunities, and OrbiMed have entered into support and voting agreements to vote their common shares in favor of the proposed transaction with XenoTherapeutics, Inc. and Xeno Acquisition Corp.The arrangement follows a definitive arrangement agreement announced on November 14, 2025 under which Xeno will acquire all issued and outstanding common shares of Repare. Combined with prior director and executive officer agreements, shareholders owning approximately 40% of Repare’s outstanding common shares have agreed to vote for the special resolution approving the transaction.

#RPTX Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

www.stocktitan.net/news/RPTX/repare-therape...

Halper Sadeh LLC Investigates Shareholder Rights for Multiple Companies Halper Sadeh LLC is investigating potential violations involving RPTX, SEE, CDTX, and MRSN shareholders. Immediate contact is encouraged.

Halper Sadeh LLC Investigates Shareholder Rights for Multiple Companies #United_States #New_York #Halper_Sadeh #RPTX #SEE

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. Repare Therapeutics (Nasdaq: RPTX) entered into a definitive arrangement agreement to be acquired by XenoTherapeutics with an estimated cash payment of $1.82 per share plus one non-transferable CVR per share. The CVR entitles holders to specified percentages of future partnership and disposition proceeds over up to a 10-year period and 100% of certain near-term receivables.The Transaction is expected to close in Q1 2026, is subject to shareholder and court approvals, and would result in delisting and deregistration. Repare reported $112.6M cash and marketable securities as of September 30, 2025, Q3 2025 revenue from collaborations of $11.6M, and net income of $3.3M for the quarter.

#RPTX Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

www.stocktitan.net/news/RPTX/repare-therape...

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Repare Therapeutics (NASDAQ:RPTX) announced significant business developments and Q2 2025 financial results. The company secured a major worldwide licensing agreement with Debiopharm for lunresertib, potentially worth up to $257 million in milestone payments plus royalties. Additionally, Repare out-licensed its discovery platforms to DCx Biotherapeutics, receiving a $1 million upfront payment and a 9.99% equity position.The company maintains $109.5 million in cash and expects key clinical data readouts in Q4 2025 from both the LIONS trial (RP-1664) and POLAR trial (RP-3467). Net loss for Q2 2025 was $16.7 million ($0.39 per share), an improvement from $34.8 million in Q2 2024. The company is actively exploring strategic alternatives to maximize shareholder value.

#RPTX Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/RPTX/repare-therape...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Wed Jul 16th - #HLLY #PKE #UCL #DPRO #CTOR #BNRG #APM #HYAC #STG #SIFY #GAME #IRIX #KITT #RPTX #QLGN #PPSI #NTWK #MEIP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Tue Jul 15th - #RPTX #MSPR #KOD #GDC #CENN #BACQ #ABOS #STC #FBK #EQBK #RVYL #VBTX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib Repare Therapeutics (NASDAQ:RPTX) has entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, a first-in-class PKMYT1 inhibitor for precision oncology. Under the agreement, Repare will receive a $10 million upfront payment and is eligible for up to $257 million in potential milestones, plus single-digit royalties on global sales.The agreement builds on their existing collaboration studying lunresertib's combination with Debio 0123, a WEE1 inhibitor. Debiopharm will take over the MYTHIC study and future development of lunresertib. Repare will focus on advancing two Phase 1 clinical trials: the LIONS trial evaluating RP-1664 (PLK4 inhibitor) and the POLAR trial evaluating RP-3467 (Polθ ATPase inhibitor), with readouts expected in Q3-Q4 2025.

#RPTX Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

www.stocktitan.net/news/RPTX/repare-therape...

Repare Therapeutics Secures Future: $124M Cash Runway Through 2027, New Strategic Partnership Repare advances oncology pipeline with $4M DCx deal, reveals Q3 clinical data timeline. Strong $124M cash position extends runway through 2027. Get full details.

#RPTX Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/RPTX/repare-therape...

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics CAMBRIDGE, Mass.& MONTREAL---- Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation, a newly-launched Canadian biotechnology company developing next generation...

#RPTX Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

www.stocktitan.net/news/RPTX/repare-therape...

Breakthrough Cancer Research: 6 New Studies Reveal Novel Drug Combinations for Ovarian and Neuroblastoma Treatment New Phase 1 MYTHIC trial data reveals drug combination efficacy in ovarian cancer. Plus breakthrough findings in neuroblastoma treatment. See complete results.

#RPTX Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

www.stocktitan.net/news/RPTX/repare-therape...

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results Repare Therapeutics (RPTX) has announced significant business restructuring and clinical updates for Q4 and full year 2024. The company is implementing a 75% workforce reduction while maintaining $152.8 million in cash reserves, extending runway to late-2027. Three key clinical trials are progressing with expected readouts in 2025:- POLAR trial (RP-3467 Polθ inhibitor) data expected Q3 2025- LIONS trial (RP-1664 PLK4 inhibitor) readout expected Q4 2025- MYTHIC trial evaluating lunresertib combination therapyFinancial highlights include revenue from collaborations of $53.5 million for 2024, reduced R&D expenses of $115.9 million (down from $133.6 million in 2023), and a net loss of $84.7 million ($2.00 per share) for 2024.

#RPTX Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/RPTX/repare-therape...

Repare Therapeutics Streamlines Pipeline, Extends Cash Runway to 2027 with Strategic Restructuring Biotech firm focuses on two key Phase 1 programs while implementing cost reductions. With $153M cash position, Repare targets important clinical readouts in Q3 2025.

#RPTX Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

www.stocktitan.net/news/RPTX/repare-therape...

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. CAMBRIDGE, Mass.& MONTREAL---- Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today reported positive data from its MYTHIC Phase 1 gynecologic...

#RPTX Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

www.stocktitan.net/news/RPTX/repare-therape...

JUST IN: ( NASDAQ: #RPTX ) Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor

#StockMarket #News

NEWS: ( NASDAQ: #RPTX ) Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

#StockMarket #News

News; ( NASDAQ: #RPTX ) Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund

#StockMarket #News